Black Diamond Therapeutics (NASDAQ: BDTX) — Perfil da empresa, notícias e dados financeiros
Black Diamond Therapeutics is a biotechnology firm focused on discovering precision medicines for genetically defined cancers.
BDTX Black Diamond Therapeutics
Perfil da empresa
Black Diamond Therapeutics
Black Diamond Therapeutics (NASDAQ:BDTX) is a biotechnology firm dedicated to discovering and developing precision medicines for cancer patients. With a focus on addressing genetically defined diseases driven by oncogenes, the company leverages its proprietary technology platform to target and inhibit elusive cancer-driving proteins. Black Diamond Therapeutics aims to unveil new treatment options for patients with limited or no existing therapeutic avenues, emphasizing a commitment to innovation and patient care in the oncology sector.
Resumo
Public USParticipação acionária
2014Ano de fundação
54Funcionários
Cambridge, United StatesSede
Carregando mapa...
Presença global
Operações
Todos os locais
Newton, US
Produtos e/ou serviços de Black Diamond Therapeutics
- Development of BDTX-1535, a targeted therapy for lung and brain cancers with specific genetic mutations.
- Creation of a platform for discovering MasterKey therapies for genetically defined cancers.
- Research on a new class of small molecule therapies designed to target allosteric mutations across multiple cancer types.
- Development of diagnostic tools to identify patients who could benefit from their MasterKey therapies.
equipe executiva do Black Diamond Therapeutics
- Mark A. VellecaCEO, President & Chairman
- Brent Hatzis-SchochCOO & General Counsel
- Sergey YurasovChief Medical Officer
- Elizabeth BuckCo-Founder & Chief Scientific Officer
- Erika JonesPrincipal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
- Melanie MorrisonChief Development Officer
Principais indicadores financeiros
Resultados divulgados pela Black Diamond Therapeutics, em USD.
- Cap. de mercado
- 105,1 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 70 mi | 19,9 mi | 22,4 mi | |
| 0 | -78,8 mi | -69,7 mi | |
| 0 | -86,5 mi | -82,4 mi | |
| 0 | -92,8 mi | -91,2 mi |